

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER OF PATENTS AND TRADEMARKS Washington, DOC 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/896.324	06/29/2001	Bi-Yu Li	TM0011-UT	8386
=27740	590 03/24/2003 ESA RESEARCH INSTI	TUTE	EXAM	INER
TORREY MESA RESEARCH INSTITUTE INTELLECTUAL PROPERTY DEPARTMENT 3115 MERRY CALL 2012	CHUNDURU, SURYAPRABHA			
SAN DIEGO,	CA 92121		ART UNIT	PAPER NUMBER
			1637	
			DATE MAILED: 03/24/2003	15

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)
		09/896,324	LI ET AL.
Office Action Summary		Examiner	Art Unit
		Suryaprabha Chunduru	1637
	The MAILING DATE of this communication app	pears on the cover sheet with	the correspondence address
Period fo	r Reply		
THE No - Exter after - If the - Failu - Any r	ORTENED STATUTORY PERIOD FOR REPLIMALING DATE OF THIS COMMUNICATION. SIX (6) MONTHS from the mailing date of this communication. Period for reply specified above is less than thirty (30) days, a reply period for reply is specified above, the maximum statutory period re to reply within the set or extended period for reply will, by statute reply received by the Office later than three months after the mailing and patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply within the statutory minimum of thirty (will apply and will expire SIX (6) MONTH	ly be timely filed (30) days will be considered timely. HS from the mailing date of this communication. NDONED (35 U.S.C. § 133).
1)[\]	Responsive to communication(s) filed on 29	J <u>une 2001</u> .	
2a)□	-	nis action is non-final.	
3)	Since this application is in condition for allow	ance except for formal matte	ers, prosecution as to the merits is
Disposit	closed in accordance with the practice under ion of Claims	Ex parte Quayle, 1935 C.D	. 11, 453 O.G. 213.
4)🛚	Claim(s) 1-23 is/are pending in the application		
	4a) Of the above claim(s) is/are withdra	wn from consideration.	
5)	Claim(s) is/are allowed.		
6)	Claim(s) is/are rejected.		
	Claim(s) is/are objected to.		
	Claim(s) 1-23 are subject to restriction and/or	election requirement.	
	tion Papers		
	The specification is objected to by the Examin		e Evaminer
10)	The drawing(s) filed on is/are: a) accomplicant may not request that any objection to t	be drawing(s) be held in abeva	nce See 37 CFR 1.85(a).
44)[]	The proposed drawing correction filed on	is: a)∏ approved b)∏ di	sapproved by the Examiner.
11)	If approved, corrected drawings are required in r		
12\[The oath or declaration is objected to by the E		
	under 35 U.S.C. §§ 119 and 120		
	Acknowledgment is made of a claim for foreign	gn priority under 35 U.S.C. §	3 119(a)-(d) or (f).
)		
u	1. Certified copies of the priority docume	nts have been received.	
	2. Certified copies of the priority document		pplication No
*	3. Copies of the certified copies of the pri application from the International E See the attached detailed Office action for a list.	ority documents have been Bureau (PCT Rule 17.2(a)).	received in this National Stage
14)	Acknowledgment is made of a claim for domes	stic priority under 35 U.S.C.	§ 119(e) (to a provisional application).
	 a) The translation of the foreign language p Acknowledgment is made of a claim for dome 	provisional application has be	een received.
Attachme		<u> </u>	
1) No	tice of References Cited (PTO-892) tice of Draftsperson's Patent Drawing Review (PTO-948) ormation Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of	Summary (PTO-413) Paper No(s) Informal Patent Application (PTO-152)

Application/Control Number: 09/896,324

Art Unit: 1637

DETAILED ACTION

Restriction/election

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
- I. Claims 1-13 and 16-21, drawn to a method for amplification and production and detection of a population of polynucleotides, classified in class 435, subclass 6, and 91.2.
- II. Claim(s) 22, drawn to a method for diagnosing a disease, condition, or disorder, classified in class 514, subclass 44.
- III. Claim(s) 14, drawn to a recombinant host cell transformed with a vector, classified in class 435, subclass 252.3.
- IV. Claim(s) 23, drawn to an isolated nucleic acid, requiring SEQ ID Nos. 2-65, classified in class 536, subclass 24.33.
- 2. The inventions are distinct, each from the other because of the following reasons:

Inventions in Group I and III are related as process of making and product made. The inventions are distinct if either or both of the following can be shown: (1) that the process as claimed can be used to make other and materially different product or (2) that the product as claimed can be made by another and materially different process (MPEP § 806.05(f)). In the instant case the product in Group III can be used in a materially different processes such as gene therapy or hybridization assays.

Inventions in Group III and II are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP

Application/Control Number: 09/896,324

Art Unit: 1637

§ 806.05(h)). In the instant case the product in Group III can be used in a materially different processes such as gene therapy or hybridization assays.

Inventions III and IV are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions the inventions in Group III and IV have different modes of operation, different functions and different results. For instance, the inventions in Group III and IV can be used independently from each other thus each product of Groups III and IV has different mode of operation with different function and effect.

Inventions I and II are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions the inventions in Group I and II have different modes of operation, different functions and different results. For instance, the invention in Group II is used to diagnose an individual with an end result of diagnosing a disease or disorder. It has different mode of operation with different function and effect.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter and the search for one group is not required for any other group, restriction for examination purposes as indicated is proper.

In this application additionally, if applicant elects Group IV, applicant is required to specify *one* specific nucleotide sequence for examination. This requirement is made under 1192 O.G. 68

Application/Control Number: 09/896,324

Art Unit: 1637

Notice (November 19, 1996 and revised MPEP), as the examination of more than one sequence in the application would result in an undue search burden on the PTO.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(I).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Suryaprabha Chunduru whose telephone number is 703-305-1004. The examiner can normally be reached on 8.30A.M. - 4.30P.M, Mon - Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Bezion can be reached on 703-308-1119. The fax phone numbers for the organization where this application or proceeding is assigned are 703-305-3014 for regular communications and - for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

Suryaprabha Chunduru

March 19, 2003

JEFFREY FREDMAN